[CAS NO. 1467093-03-3] Adavivint (SM04690)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1467093-03-3]
Catalog
SLK-S8761
Brand
Selleck
CAS
1467093-03-3
DESCRIPTION [1467093-03-3]
Overview
| MDL | MFCD30489411 |
|---|---|
| Molecular Weight | 505.55 |
| Molecular Formula | C29H24FN7O |
| SMILES | CC(C)CC(NC1=CC(C2=CC3=C(NN=C3C(N4)=NC5=C4C=NC=C5C6=CC=CC(F)=C6)C=C2)=CN=C1)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9780 mL | 9.8902 mL | 19.7804 mL |
| 5 mM | 0.3956 mL | 1.9780 mL | 3.9561 mL |
| 10 mM | 0.1978 mL | 0.9890 mL | 1.9780 mL |
| 50 mM | 0.0396 mL | 0.1978 mL | 0.3956 mL |
Description
Adavivint (SM04690,Lorecivivint) is a potent and specific inhibitor of with an EC50 of 19.5 nM for inhibiting the TCF/LEF reporter. It is ∼150- to 500-fold more potent than the other known Wnt inhibitors across multiple cellular assays.
Targets
| Wnt [1] |
In vitro
Bone-marrow-derived hMSCs (CD29+, CD44+ CD166+ CD105+ CD45-), treated with SM04690, show a dose-dependent decrease in the expression of Wnt pathway genes (ASCL1, LEF1, TCF7L2, TCF7, C-262 MYC and AXIN2). M04690 also inhibits the expression of AXIN2, TCF7 and LEF1 in hMSCs and AXIN2 and LGR5 in IEC6 (intestinal stem cells sensitive to Wnt activation) when the Wnt pathway is selectively activated using either Wnt3a or a GSK3β inhibitor, CHIR-99021. SM04690 has minimal effects on the non-canonical Wnt pathway and the BMP pathway. SM04690 protects chondrocytes from catabolic breakdown in vitro.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.